연골 수복 및 재생 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, cartilage repair/regeneration market size in 2026 is estimated at USD 1.96 billion, growing from 2025 value of USD 1.73 billion with 2031 projections showing USD 3.69 billion, growing at 13.44% CAGR over 2026-2031.

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating Global Incidence Of Osteoarthritis And Traumatic Cartilage Lesions
  • 4.2.2 Surge In Outpatient Minimally Invasive Orthopedic Procedures
  • 4.2.3 Breakthroughs In Tissue-Engineered Scaffolds And Cell-Based Implants
  • 4.2.4 Increasing Participation In High-Impact And Recreational Sports, Elevating Injury Volumes That Require Cartilage Repair
  • 4.2.5 Increasing Reimbursement Coverage For Biologic Knee Restoration Across Major Markets
  • 4.2.6 Expanding Participation In High-Impact Sports Raising Injury Volumes
• 4.3 Market Restraints
  • 4.3.1 High Procedure And Implant Costs Limiting Uptake In Price-Sensitive Regions
  • 4.3.2 Lengthy And Complex Regulatory Approval Pathways For Advanced Therapies
  • 4.3.3 Limited Long-Term Clinical Durability Data Curbing Surgeon Confidence
  • 4.3.4 Supply Constraints Of Qualified Donor Tissue And Gmp Manufacturing Capacity
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory & Technological Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value)

• 5.1 By Types of Cartilage
  • 5.1.1 Hyaline Cartilage
  • 5.1.2 Fibrocartilage
  • 5.1.3 Elastic / Other Cartilage
• 5.2 By Treatment Modality
  • 5.2.1 Cell-based Therapies
  • 5.2.2 Non-cell-based / Cell-free Therapies
• 5.3 By Treatment Type
  • 5.3.1 Palliative (Debridement, Viscosupplementation)
  • 5.3.2 Intrinsic Repair Stimulus (ACI, MACI, Micro-fracture)
• 5.4 By Surgical Technique
  • 5.4.1 Chondroplasty & Micro-fracture
  • 5.4.2 Autologous Chondrocyte Implantation (ACI)
  • 5.4.3 Matrix-induced ACI (MACI)
  • 5.4.4 Osteochondral Allograft / Juvenile Allograft
• 5.5 By Application Site
  • 5.5.1 Knee
  • 5.5.2 Hip
  • 5.5.3 Ankle
  • 5.5.4 Spine
  • 5.5.5 Other Joints (Shoulder, Elbow, Wrist)
• 5.6 By End User
  • 5.6.1 Hospitals & Clinics
  • 5.6.2 Ambulatory Surgical Centers
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East & Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East & Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Arthrex Inc.
  • 6.3.2 Stryker
  • 6.3.3 Zimmer Biomet
  • 6.3.4 Smith + Nephew
  • 6.3.5 Johnson & Johnson (DePuy Synthes)
  • 6.3.6 Vericel Corporation
  • 6.3.7 Anika Therapeutics Inc.
  • 6.3.8 B. Braun SE
  • 6.3.9 Geistlich Pharma AG
  • 6.3.10 CYFUSE Biomedical K.K.
  • 6.3.11 Conmed Corporation
  • 6.3.12 MEDIPOST
  • 6.3.13 CartiHeal Ltd.
  • 6.3.14 Askel Healthcare Oy
  • 6.3.15 BioTissue
  • 6.3.16 Collagen Solutions PLC
  • 6.3.17 Matricel GmbH
  • 6.3.18 Orthocell Ltd.
  • 6.3.19 Osiris Therapeutics
  • 6.3.20 Autocart Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment